髓样分化蛋白2(MD2)在血管紧张素II(AngII)诱导的炎症反应及心室重构中的作用和机制研究
批准号:
81670244
项目类别:
面上项目
资助金额:
57.0 万元
负责人:
黄伟剑
依托单位:
学科分类:
心肌损伤、修复、重构和再生
结题年份:
2020
批准年份:
2016
项目状态:
已结题
项目参与者:
潘勇、单培仁、刘俊、陈凌峰、韩集波、尤圣办、郑海伦
中文摘要
血管紧张素II(AngII)在心室重构中有着重要作用。除调节血压外,AngII还可以通过炎症直接介导心室重构,但该过程的机制尚不清楚。在内毒素诱导的炎症反应中,Toll样受体4(TLR4)和髓样分化蛋2(MD2)共同发挥着重要作用。虽研究表明TLR4参与了AngII诱导的炎症及心室重构,但其直接机制有待阐明。我们前期研究发现一个MD2小分子抑制剂L6H21可以抑制AngII诱导的炎症反应,并在体内显著缓解心脏炎症和心室重构。基于此,我们假设:1)MD2在AngII诱导的炎症反应中起重要的介导作用;2)MD2可以作为缓解心室重构的新靶点。本项目拟从分子、细胞和动物三个层面,深入阐明MD2介导AngII诱导的炎症反应和心室重构的分子机制,证实AngII通过直接结合MD2并引起MD2/TLR4炎症信号通路激活的促炎机制。项目将阐明AngII促炎机制并为缓解心室重构及减慢心力衰竭提供新的治疗靶点
英文摘要
Angiotensin II (AngII) has an important role in the biological process leading to cardiac remodeling. In addition to its physiological role in arterial blood pressure regulation, AngII directly induces myocardial remodeling through the inflammation. However, it remains an open question to precisely describe how inflammation is activated by AngII, resulting in the remodeling in heart.TLR4 and MD2 play important roles in LPS-induced inflammation. Although TLR4 has been demonstrated as an important regulator in cardiac remodeling, the direct mechanism remains to be elucidated. Our previous study found that a novel small molecule L6H21, which targets MD2 protein and inhibits LPS-induced inflammatory response, could inhibit AngII-induced inflammation and cardiac remodeling development in vivo. Thus, we hypothesize that, MD2 plays an important role in mediating AngII-induced inflammation and MD2 may be a new target for the treatment of cardiac remodeling. In this project, we plan to demonstrate the mechanisms of MD2 in AngII-induced inflammation and cardiac remodeling and prove the mechanisms that AngII binding directly with MD2 is required in activation of the TLR4/MD2 inflammatory signals in the molecular, cellular, and animal levels. These studies will demonstrate the effects and mechanisms of AngII-induced inflammation and provide a new therapeutic target for cardiac remodeling and heart failure treatment.
本项目总目标在于明确MD2介导的炎症在高血压心衰的发生发展中的重要作用,证实MD2可以作为缓解高血压心衰的新靶点,阐明前期发现的以MD2为直接靶点的新化合物L6H21缓解高血压心衰的药理分子机制。 .我们前期的实验过程中发现L6H21是MD2蛋白的小分子抑制剂,且化合物L6H21能够缓解LPS诱导的脓毒血症和急性肺损伤的表型。本项目的实施阐明了MD2介导高血压心衰的药理机制,确证了MD2可以作为缓解高血压心衰的新靶点,为动高血压心衰的治疗提供了新的候选药物。本项目的实施完成了申请书中的项目目标。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
登录
查看更多内容
Macrophage-derived myeloid differentiation protein 2 plays an essential role in ox-LDL-induced inflammation and atherosclerosis
巨噬细胞源性骨髓分化蛋白 2 在 ox-LDL 诱导的炎症和动脉粥样硬化中发挥重要作用
DOI:
10.1016/j.ebiom.2020.102706
发表时间:
2020-03-01
期刊:
EBIOMEDICINE
影响因子:
11.1
作者:
[Chen, Taiwei, Huang, Weijian, Liang, Guang]
通讯作者:
Liang, Guang
MD2 Blockage Protects Obesity-Induced Vascular Remodeling via Activating AMPK/Nrf2
MD2 阻断通过激活 AMPK/Nrf2 保护肥胖引起的血管重塑
DOI:
10.1002/oby.21916
发表时间:
2017-09-01
期刊:
OBESITY
影响因子:
6.9
作者:
[Wang, Lintao, Han, Jibo, Liang, Guang]
通讯作者:
Liang, Guang
Inhibition of myeloid differentiation factor-2 attenuates obesity-induced cardiomyopathy and fibrosis
抑制骨髓分化因子 2 可减轻肥胖引起的心肌病和纤维化
DOI:
10.1016/j.bbadis.2017.09.026
发表时间:
2018-01-01
期刊:
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
影响因子:
6.2
作者:
[Fang, Qilu, Wang, Jingying, Wang, Yi]
通讯作者:
Wang, Yi
Schizandrin B attenuates angiotensin II induced endothelial to mesenchymal transition in vascular endothelium by suppressing NF-κB activation
五味子素 B 通过抑制 NF-κ B 激活来减弱血管紧张素 II 诱导的血管内皮细胞向间质转化
DOI:
10.1016/j.phymed.2019.152955
发表时间:
2019-09-01
期刊:
PHYTOMEDICINE
影响因子:
7.9
作者:
[You Shengban, Qian Jianchang, Liang Guang]
通讯作者:
Liang Guang
hsa_circRNA_0007478/miR-765调控巨噬细胞焦亡介导动脉粥样硬化炎症反应的作用研究
-
批准号:82070446
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:黄伟剑
-
依托单位:
髓样分化蛋白-2在动脉粥样硬化发生发展中介导炎症反应的作用机制和干预研究
-
批准号:81470565
-
项目类别:面上项目
-
资助金额:68.0万元
-
批准年份:2014
-
负责人:黄伟剑
-
依托单位:
国内基金
海外基金